MX2024013485A - Formas salinas y cristalinas de un inhibidor del receptor del factor de crecimiento epidermico - Google Patents

Formas salinas y cristalinas de un inhibidor del receptor del factor de crecimiento epidermico

Info

Publication number
MX2024013485A
MX2024013485A MX2024013485A MX2024013485A MX2024013485A MX 2024013485 A MX2024013485 A MX 2024013485A MX 2024013485 A MX2024013485 A MX 2024013485A MX 2024013485 A MX2024013485 A MX 2024013485A MX 2024013485 A MX2024013485 A MX 2024013485A
Authority
MX
Mexico
Prior art keywords
growth factor
factor receptor
epidermal growth
salt
crystalline forms
Prior art date
Application number
MX2024013485A
Other languages
English (en)
Spanish (es)
Inventor
Eric Gruff
Shanming Kuang
Anjali Pandey
Harsh Shah
Tian Xie
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of MX2024013485A publication Critical patent/MX2024013485A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2024013485A 2022-05-04 2024-10-31 Formas salinas y cristalinas de un inhibidor del receptor del factor de crecimiento epidermico MX2024013485A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263338371P 2022-05-04 2022-05-04
PCT/US2023/020925 WO2023215431A1 (en) 2022-05-04 2023-05-04 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
MX2024013485A true MX2024013485A (es) 2024-12-06

Family

ID=86688767

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013485A MX2024013485A (es) 2022-05-04 2024-10-31 Formas salinas y cristalinas de un inhibidor del receptor del factor de crecimiento epidermico

Country Status (12)

Country Link
US (1) US20250282761A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519254A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517634A (cg-RX-API-DMAC7.html)
KR (1) KR20250012078A (cg-RX-API-DMAC7.html)
CN (1) CN119923392A (cg-RX-API-DMAC7.html)
AU (1) AU2023265064A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251624A1 (cg-RX-API-DMAC7.html)
IL (1) IL316663A (cg-RX-API-DMAC7.html)
MX (1) MX2024013485A (cg-RX-API-DMAC7.html)
TW (1) TW202409016A (cg-RX-API-DMAC7.html)
UY (1) UY40256A (cg-RX-API-DMAC7.html)
WO (1) WO2023215431A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202432143A (zh) * 2022-11-01 2024-08-16 美商纜圖藥品公司 用於治療癌症之egfr抑制劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
EP4237418B1 (en) * 2020-10-30 2026-02-11 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof
EP4237088A1 (en) * 2020-10-30 2023-09-06 Blueprint Medicines Corporation Pyrimidine compounds, compositions, and medicinal applications thereof

Also Published As

Publication number Publication date
UY40256A (es) 2023-11-15
JP2025517634A (ja) 2025-06-10
AU2023265064A1 (en) 2024-11-14
TW202409016A (zh) 2024-03-01
EP4519254A1 (en) 2025-03-12
KR20250012078A (ko) 2025-01-23
WO2023215431A1 (en) 2023-11-09
US20250282761A1 (en) 2025-09-11
CN119923392A (zh) 2025-05-02
IL316663A (en) 2024-12-01
CA3251624A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
CL2022001731A1 (es) Inhibidores de egfr.
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
EP4566612A3 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
JOP20240216A1 (ar) مثبطات kras g12c
CO2025013134A2 (es) Inhibidores de kras
CL2024000067A1 (es) Compuestos antivirales
MX2025008591A (es) Inhibidores de cdk
EA202092558A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА ИНГИБИТОРА c-MET, ЕГО СОЛЕВАЯ ФОРМА И СПОСОБ ИХ ПОЛУЧЕНИЯ
MX2020007014A (es) Compuestos de benzamida.
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
SA522441624B1 (ar) مثبطات إنزيمات كيناز مستقبل عامل نمو الأرومة الليفية
PY2005283A (es) Inhibidores de cdk2
CR20240408A (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2.
CL2023001367A1 (es) Inhibidores de btk
MX2021000014A (es) Derivados de quinazolina tipo eter biarilico.
CL2024002461A1 (es) Síntesis de compuestos de quinazolina
CR20240014A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
GT200600215A (es) Metodos para sintetizar derivados de 6-alquilaminoquinolina
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
AR130287A1 (es) Métodos para la fabricación de inhibidores de quinasa
DOP2025000212A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2024012267A (es) Inhibidores de egfr
EA202192760A1 (ru) Трициклические соединения